Free equity investment tool of Japanese companies

Financial Indicator Details

Annual

First quarter

Second quarter

Third quarter

Sponsored Link

Related Company

Takeda Pharmaceutical

キョーリン製薬ホールディングス

Nissan Chemical Industries

TSUMURA & CO.

Mitsubishi Tanabe Pharma

ADEKA

ダイセル

Otsuka Holdings

Toray Industries

千寿製薬

Dainippon Sumitomo Pharma

Kuraray

Nichi-Iko Pharmaceutical

キッセイ薬品工業

Hitachi Chemical

EDIUNET Related Ranking

EDIUNET

EDIUNET Credit Rating

EDIUNET Industry Avg

EDIUNET Prefectures

Yuho! Industry

EDIUNET Rating News

Prev « 2024-04 » Next

Mon	Tue	Wed	Thu	Fri	Sat	Sun
1 -	2 -	3 -	4 -	5 -	6 -	7 -
8 -	9 -	10 -	11 -	12 -	13 -	14 -
15 -	16 -	17 -	18 -	19 -	20 -	21 -
22 -	23 -	24 -	25 -	26 -	27 -	28 -
29 -	30 -

[Update list]

1/28 Retail Trade (CAWACHI:A etc...

1/27 Banks (The Awa Bank:BBB→A)

1/23 Chemicals (Milbon:AA→AAA)

1/21 Glass & Ceramics Products (..

1/21 Machinery (TSUDAKOMA:C)

1/21 Other Services (Netindex.:CC)

1/20 Other Products (Kurogane Kos..

1/20 Wholesale Trade (リーバイ・..

1/20 Other Services (川崎地質:BB→..

1/17 Chemicals (Kawaguchi Chemica..

 RSS

 Company RSS

 Daily RSS

Sponsored Link

Recently Download Chart

メルコホールディングス

Yushiro Chemical Indutry

PIONEER

NITCHITSU　

ROHM

Financial Indicator Details: Takeda Pharmaceutical (Annual )

Two or more periods are displayed by each of financial indicator collectively.Two or more companies can be compared and financial indicator data can also be downloaded.

【Analysis Menu】 Outline Statement Rating Indicator Download

Sponsored Link

*Free Download Financial Indicator data

Indicator Summary: Takeda Pharmaceutical (Annual )

Consolidated :Indicator Consolidated | Non-Consolidated

Profitability	2009-03-31	2010-03-31	2011-03-31	2012-03-31	2013-03-31
Net profit margin (Industry Average)	15.23% (-12.05%)	20.31% (-0.50%)	17.46% (1.53%)	8.22% (-1.67%)	8.42% (3.05%)
C/F margin (Industry Average)	21.20% (-3.31%)	26.00% (8.51%)	23.03% (7.04%)	22.30% (6.35%)	19.75% (8.25%)
ROA (Industry Average)	8.49% (0.52%)	10.54% (1.04%)	8.89% (2.07%)	3.47% (0.06%)	3.31% (2.71%)
ROE (Industry Average)	11.41% (-1.43%)	13.75% (0.03%)	11.60% (2.96%)	5.99% (4.68%)	5.90% (4.57%)
Growth	2009-03-31	2010-03-31	2011-03-31	2012-03-31	2013-03-31
Equity growth (Industry Average)	- (-)	5.39% (5.01%)	-1.29% (2.61%)	-3.03% (-0.40%)	7.31% (8.16%)
Sales growth (Industry Average)	- (-)	-4.70% (-2.67%)	-3.17% (5.36%)	6.30% (1.07%)	3.20% (2.24%)
Net profit growth (Industry Average)	- (-)	27.03% (203.46%)	-16.75% (63.25%)	-49.90% (3.89%)	5.70% (90.38%)
Operating C/F growth (Industry Average)	- (-)	16.82% (275.10%)	-14.22% (35.09%)	2.94% (-6.09%)	-8.57% (138.39%)
Stability	2009-03-31	2010-03-31	2011-03-31	2012-03-31	2013-03-31
Capital adequacy (Industry Average)	74.40% (53.80%)	76.67% (54.51%)	76.68% (55.00%)	57.92% (53.59%)	56.20% (56.30%)
Liquidity ratio (Industry Average)	312.55% (217.72%)	367.08% (225.70%)	363.32% (237.55%)	170.14% (239.89%)	237.12% (236.21%)
C/F ratio current liabilities (Industry Average)	144.69% (777.21%)	112.41% (303.31%)	133.54% (434.79%)	223.35% (929.73%)	199.41% (573.30%)
Quick ratio (Industry Average)	112.66% (138.97%)	127.70% (148.85%)	117.24% (156.17%)	74.43% (160.84%)	103.50% (156.81%)
Turnover	2009-03-31	2010-03-31	2011-03-31	2012-03-31	2013-03-31
Receivables turnover (Industry Average)	71.74day (83.89day)	69.87day (94.27day)	75.60day (93.96day)	83.37day (97.92day)	80.98day (98.27day)
Inventory turnover (Industry Average)	31.23day (54.45day)	34.28day (52.58day)	35.26day (52.64day)	47.17day (56.59day)	53.79day (58.68day)
Payable turnover (Industry Average)	16.16day (45.01day)	18.13day (49.82day)	21.36day (49.52day)	24.66day (52.10day)	27.81day (51.12day)
Working capita turnover (Industry Average)	86.81day (93.32day)	86.03day (97.02day)	89.50day (97.08day)	105.88day (102.41day)	106.96day (105.83day)
Stock etc.	2009-03-31	2010-03-31	2011-03-31	2012-03-31	2013-03-31
Market Value growth (Industry Average)	- (-)	21.02% (34.57%)	-5.71% (1.49%)	-6.05% (-3.85%)	37.99% (21.16%)
Dividend Yield (Industry Average)	5.30% (3.20%)	4.41% (1.93%)	4.63% (2.17%)	4.93% (2.45%)	3.57% (2.07%)
PER (Industry Average)	11.45% (25.22%)	10.91% (23.06%)	12.36% (16.22%)	23.18% (29.19%)	30.26% (16.58%)
PBR (Industry Average)	1.30% (0.86%)	1.50% (1.06%)	1.43% (1.04%)	1.38% (0.95%)	1.78% (1.08%)
PCFR (Industry Average)	8.22% (7.18%)	8.52% (9.23%)	9.37% (-2.43%)	8.55% (9.50%)	12.90% (7.56%)
PSR (Industry Average)	1.74% (0.77%)	2.21% (0.88%)	2.15% (1.10%)	1.90% (0.90%)	2.55% (1.01%)

Non-Consolidated :Indicator Consolidated | Non-Consolidated

Profitability	2009-03-31	2010-03-31	2011-03-31	2012-03-31	2013-03-31
Net profit margin (Industry Average)	17.10% (-27.66%)	23.67% (-4.34%)	16.13% (-5.37%)	44.62% (-10.69%)	19.65% (8.92%)
C/F margin (Industry Average)	- (0.87%)	- (1.04%)	- (0.82%)	- (-0.81%)	- (-39.63%)
ROA (Industry Average)	10.16% (0.52%)	13.40% (0.92%)	8.76% (1.42%)	15.86% (-0.27%)	6.40% (1.53%)
ROE (Industry Average)	12.33% (-0.84%)	16.10% (-0.46%)	10.73% (1.81%)	24.80% (3.42%)	10.16% (2.62%)
Growth	2009-03-31	2010-03-31	2011-03-31	2012-03-31	2013-03-31
Equity growth (Industry Average)	- (-)	5.72% (3.64%)	-1.27% (3.03%)	18.71% (0.04%)	1.75% (3.91%)
Sales growth (Industry Average)	- (-)	-0.26% (-3.48%)	-3.40% (6.70%)	-0.86% (0.75%)	-5.37% (-1.74%)
Net profit growth (Industry Average)	- (-)	38.02% (166.48%)	-34.17% (43.48%)	174.24% (-47.04%)	-58.31% (62.14%)
Operating C/F growth (Industry Average)	- (-)	- (89.80%)	- (77.44%)	- (-44.41%)	- (46.89%)
Stability	2009-03-31	2010-03-31	2011-03-31	2012-03-31	2013-03-31
Capital adequacy (Industry Average)	82.39% (56.79%)	83.21% (57.65%)	81.57% (57.17%)	63.93% (55.93%)	62.98% (57.57%)
Liquidity ratio (Industry Average)	290.29% (337.22%)	300.64% (276.75%)	240.73% (266.94%)	121.47% (314.47%)	- (233.84%)
C/F ratio current liabilities (Industry Average)	- (48.90%)	- (53.10%)	- (31.35%)	- (76.77%)	- (31.87%)
Quick ratio (Industry Average)	96.71% (167.28%)	114.15% (183.78%)	97.70% (174.83%)	46.64% (228.06%)	- (169.77%)
Turnover	2009-03-31	2010-03-31	2011-03-31	2012-03-31	2013-03-31
Receivables turnover (Industry Average)	75.99day (87.55day)	70.48day (98.39day)	82.28day (95.88day)	81.93day (98.58day)	- (67.18day)
Inventory turnover (Industry Average)	34.65day (50.17day)	38.61day (48.43day)	41.52day (47.43day)	46.01day (50.67day)	- (38.21day)
Payable turnover (Industry Average)	19.99day (45.70day)	19.62day (51.63day)	24.97day (51.13day)	25.22day (53.57day)	- (34.24day)
Working capita turnover (Industry Average)	90.65day (92.02day)	89.47day (95.19day)	98.83day (92.19day)	102.72day (95.69day)	- (71.15day)
Stock etc.	2009-03-31	2010-03-31	2011-03-31	2012-03-31	2013-03-31
Market Value growth (Industry Average)	- (-)	21.02% (34.46%)	-5.71% (3.11%)	-6.05% (-3.30%)	37.99% (24.19%)
Dividend Yield (Industry Average)	- (0.15%)	- (0.09%)	- (0.10%)	- (0.16%)	- (0.15%)
PER (Industry Average)	17.95% (34.12%)	15.74% (27.80%)	22.55% (13.58%)	7.72% (22.26%)	25.57% (26.42%)
PBR (Industry Average)	2.21% (0.97%)	2.53% (1.21%)	2.42% (1.17%)	1.91% (1.08%)	2.59% (1.54%)
PCFR (Industry Average)	- (0.27%)	- (0.62%)	- (0.23%)	- (0.08%)	- (4.97%)
PSR (Industry Average)	3.07% (3.42%)	3.72% (4.34%)	3.63% (3.67%)	3.44% (4.37%)	5.02% (10.14%)

Financial Indicator Details: Takeda Pharmaceutical

Consolidated :Indicator Consolidated | Non-Consolidated

Indicator	2009-03-31	2010-03-31	2011-03-31	2012-03-31	2013-03-31
Profitability
Net profit margin	15.23%	20.31%	17.46%	8.22%	8.42%
C/F margin	21.20%	26.00%	23.03%	22.30%	19.75%
ROA	8.49%	10.54%	8.89%	3.47%	3.31%
ROE	11.41%	13.75%	11.60%	5.99%	5.90%
Recurring margin	21.26%	28.36%	26.17%	17.91%	7.26%
EBIT margin	25.27%	28.32%	26.15%	16.73%	8.46%
EBITDA margin	31.98%	35.13%	32.67%	25.21%	19.16%
NOPAT margin	15.16%	16.99%	15.69%	10.03%	5.07%
Sales SG rates	18.82%	19.44%	22.37%	28.70%	28.74%
Sales SG&A rates	61.25%	51.89%	51.76%	53.72%	63.38%
Sales R&D expenses rates	-	-	-	-	-
Sales depreciation rates	6.71%	6.80%	6.52%	8.48%	10.70%
Capital expenditures net sales ratio	-2.56%	-5.93%	-8.74%	-4.10%	-5.02%
Indicator	2009-03-31	2010-03-31	2011-03-31	2012-03-31	2013-03-31
Growth
Growth rate of cash	-	16.12%	-18.24%	-1.38%	34.77%
Equity growth	-	5.39%	-1.29%	-3.03%	7.31%
Total assets growth	-	2.28%	-1.30%	28.37%	10.58%
Sales growth	-	-4.70%	-3.17%	6.30%	3.20%
Net profit growth	-	27.03%	-16.75%	-49.90%	5.70%
Operating C/F growth	-	16.82%	-14.22%	2.94%	-8.57%
Recurring profit growth	-	27.08%	-10.64%	-27.24%	-58.13%
EBIT growth	-	6.81%	-10.62%	-31.98%	-47.78%
EBITDA growth	-	4.67%	-9.95%	-17.97%	-21.54%
NOPAT growth	-	6.81%	-10.62%	-31.98%	-47.78%
Operating expenses growth	-	-	-	-	-
Indicator	2009-03-31	2010-03-31	2011-03-31	2012-03-31	2013-03-31
Stability
Capital adequacy	74.40%	76.67%	76.68%	57.92%	56.20%
Liquidity ratio	312.55%	367.08%	363.32%	170.14%	237.12%
C/F ratio current liabilities	144.69%	112.41%	133.54%	223.35%	199.41%
Quick ratio	112.66%	127.70%	117.24%	74.43%	103.50%
Fixed ratio	12.58%	14.73%	19.07%	23.58%	22.98%
D/E ratio	0.15%	0.15%	0.12%	26.19%	24.37%
Loan to Value Ratio	0.11%	0.11%	0.09%	15.17%	13.70%
Business investment C/F ratio	-12.09%	-22.81%	-37.97%	-18.39%	-25.41%
Liabilities with interest growth	-	2.20%	-21.00%	20,817.30%	-0.15%
Indicator	2009-03-31	2010-03-31	2011-03-31	2012-03-31	2013-03-31
Turnover
Cash turnover	54.46day	66.36day	56.03day	51.97day	67.88day
Receivables turnover	71.74day	69.87day	75.60day	83.37day	80.98day
Inventory turnover	31.23day	34.28day	35.26day	47.17day	53.79day
Fixed assets turnover	61.33day	79.41day	104.78day	118.21day	119.79day
Total asset turnover	654.90day	702.94day	716.53day	865.25day	927.13day
Payable turnover	16.16day	18.13day	21.36day	24.66day	27.81day
Capital turnover	15.07day	15.82day	16.33day	15.37day	14.89day
Equity turnover	487.31day	538.98day	549.44day	501.16day	521.12day
Working capita turnover	86.81day	86.03day	89.50day	105.88day	106.96day
Indicator	2009-03-31	2010-03-31	2011-03-31	2012-03-31	2013-03-31
Balance sheet
Cash etc.	¥ 229 B	¥ 266 B	¥ 217 B	¥ 214 B	¥ 289 B
Accounts receivable-trade	¥ 302 B	¥ 280 B	¥ 293 B	¥ 344 B	¥ 345 B
Other Current Assets	¥ 1.2 T	¥ 1.3 T	¥ 1.3 T	¥ 1.0 T	¥ 1.1 T
Current Assets	¥ 1.4 T	¥ 1.5 T	¥ 1.5 T	¥ 1.2 T	¥ 1.4 T
Tangible Assets	¥ 258 B	¥ 318 B	¥ 407 B	¥ 488 B	¥ 511 B
Intangible Assets	¥ 747 B	¥ 639 B	¥ 517 B	¥ 1.5 T	¥ 1.6 T
Investment etc.	¥ 278 B	¥ 291 B	¥ 275 B	¥ 293 B	¥ 299 B
Total Assets	¥ 2.7 T	¥ 2.8 T	¥ 2.7 T	¥ 3.5 T	¥ 3.9 T
Current Liabilities	¥ 472 B	¥ 428 B	¥ 436 B	¥ 751 B	¥ 613 B
Fixed Liabilities	¥ 234 B	¥ 230 B	¥ 213 B	¥ 753 B	¥ 1.1 T
Liabilities with interest	¥ 3 B	¥ 3 B	¥ 2 B	¥ 542 B	¥ 541 B
Net Assets	¥ 2.0 T	¥ 2.1 T	¥ 2.1 T	¥ 2.0 T	¥ 2.2 T
Capital stock	¥ 63 B	¥ 63 B	¥ 63 B	¥ 63 B	¥ 63 B
Capital surplus etc.	¥ 1.9 T	¥ 2.1 T	¥ 2.0 T	¥ 2.0 T	¥ 2.1 T
Liabilities and net assets	¥ 2.7 T	¥ 2.8 T	¥ 2.7 T	¥ 3.5 T	¥ 3.9 T
Indicator	2009-03-31	2010-03-31	2011-03-31	2012-03-31	2013-03-31
Income statement
Sales	¥ 1.5 T	¥ 1.4 T	¥ 1.4 T	¥ 1.5 T	¥ 1.5 T
Cost of Sales	¥ 289 B	¥ 285 B	¥ 317 B	¥ 433 B	¥ 447 B
Gross profit	¥ 1.2 T	¥ 1.1 T	¥ 1.1 T	¥ 1.0 T	¥ 1.1 T
Other income	¥ 114 B	¥ 25 B	¥ 30 B	¥ 40 B	¥ 122 B
SG&A	¥ 942 B	¥ 760 B	¥ 734 B	¥ 810 B	¥ 987 B
Other expenses	¥ 183 B	¥ 145 B	¥ 147 B	¥ 178 B	¥ 111 B
Net income	¥ 234 B	¥ 297 B	¥ 247 B	¥ 124 B	¥ 131 B
Operating income	¥ 306 B	¥ 420 B	¥ 367 B	¥ 265 B	¥ 122 B
Ordinary Income	¥ 327 B	¥ 415 B	¥ 371 B	¥ 270 B	¥ 113 B
EBITDA	¥ 492 B	¥ 515 B	¥ 463 B	¥ 380 B	¥ 298 B
Income before income taxes	¥ 398 B	¥ 415 B	¥ 371 B	¥ 252 B	¥ 129 B
Depreciation	¥ 103 B	¥ 99 B	¥ 92 B	¥ 127 B	¥ 166 B
R&D expenses	-	-	-	-	-
Income taxes	¥ 161 B	¥ 115 B	¥ 121 B	¥ 125 B	¥ -3 B
Indicator	2009-03-31	2010-03-31	2011-03-31	2012-03-31	2013-03-31
Cash flow statement
Operating CF	¥ 326 B	¥ 381 B	¥ 326 B	¥ 336 B	¥ 307 B
Investment CF	¥ -767 B	¥ -117 B	¥ -99 B	¥ -1.0 T	¥ -111 B
Financial CF	¥ -425 B	¥ -148 B	¥ -146 B	¥ 393 B	¥ -150 B
Foreign Exchange Effects	¥ 11 B	¥ -21 B	¥ -60 B	¥ -54 B	¥ 45 B
Net Change in Cash	¥ -855 B	¥ 94 B	¥ 20 B	¥ -418 B	¥ 91 B
Free CF	¥ -440 B	¥ 263 B	¥ 227 B	¥ -757 B	¥ 196 B
Capital expenditures	¥ -39 B	¥ -86 B	¥ -124 B	¥ -61 B	¥ -78 B
Cash dividends paid	¥ -142 B	¥ -143 B	¥ -142 B	¥ -142 B	¥ -142 B
Repayment loans	¥ -800 M	-	¥ -1 B	¥ -72 M	¥ -213 M
Indicator	2009-03-31	2010-03-31	2011-03-31	2012-03-31	2013-03-31
Shareowners' equity
Issuance of new shares	-	-	-	-	-
Dividends from surplus	¥ -142 B	¥ -143 B	¥ -142 B	¥ -142 B	¥ -142 B
Net income	¥ 234 B	¥ 297 B	¥ 247 B	¥ 124 B	¥ 131 B
Purchase of treasury stock	¥ -280 B	¥ 77 M	¥ -35 M	¥ 156 M	¥ 128 M
Other Change in Stockholders Equity	-	-	-	-	¥ -10 B
Other Change in Net Assets	¥ -78 B	¥ -43 B	¥ -133 B	¥ -47 B	¥ 172 B
Net Change in Net Assets	¥ -267 B	¥ 110 B	¥ -28 B	¥ -64 B	¥ 151 B

Financial Indicator Details: Takeda Pharmaceutical

Non-Consolidated :Indicator Consolidated | Non-Consolidated

Indicator	2009-03-31	2010-03-31	2011-03-31	2012-03-31	2013-03-31
Profitability
Net profit margin	17.10%	23.67%	16.13%	44.62%	19.65%
C/F margin	-	-	-	-	-
ROA	10.16%	13.40%	8.76%	15.86%	6.40%
ROE	12.33%	16.10%	10.73%	24.80%	10.16%
Recurring margin	30.84%	29.50%	23.03%	54.11%	12.18%
EBIT margin	26.72%	29.43%	23.04%	56.29%	-
EBITDA margin	26.74%	29.43%	23.04%	56.29%	-
NOPAT margin	16.03%	17.66%	13.82%	33.77%	-
Sales SG rates	26.11%	26.18%	31.02%	32.53%	80.34%
Sales SG&A rates	46.00%	45.43%	47.30%	46.04%	-
Sales R&D expenses rates	-	-	-	-	-
Sales depreciation rates	0.01%	-	-	-	-
Capital expenditures net sales ratio	-	-	-	-	-
Indicator	2009-03-31	2010-03-31	2011-03-31	2012-03-31	2013-03-31
Growth
Growth rate of cash	-	105.51%	-37.65%	-17.59%	-100.00%
Equity growth	-	5.72%	-1.27%	18.71%	1.75%
Total assets growth	-	4.69%	0.71%	51.46%	3.30%
Sales growth	-	-0.26%	-3.40%	-0.86%	-5.37%
Net profit growth	-	38.02%	-34.17%	174.24%	-58.31%
Operating C/F growth	-	-	-	-	-
Recurring profit growth	-	-4.62%	-24.59%	132.92%	-78.68%
EBIT growth	-	9.82%	-24.37%	142.17%	-100.00%
EBITDA growth	-	9.76%	-24.37%	142.17%	-100.00%
NOPAT growth	-	9.82%	-24.37%	142.17%	-100.00%
Operating expenses growth	-	-	-	-	-
Indicator	2009-03-31	2010-03-31	2011-03-31	2012-03-31	2013-03-31
Stability
Capital adequacy	82.39%	83.21%	81.57%	63.93%	62.98%
Liquidity ratio	290.29%	300.64%	240.73%	121.47%	-
C/F ratio current liabilities	-	-	-	-	-
Quick ratio	96.71%	114.15%	97.70%	46.64%	-
Fixed ratio	9.28%	13.45%	21.30%	19.06%	-
D/E ratio	-	-	-	37.90%	-
Loan to Value Ratio	-	-	-	24.23%	-
Business investment C/F ratio	-	-	-	-	-
Liabilities with interest growth	-	-	-	-	-100.00%
Indicator	2009-03-31	2010-03-31	2011-03-31	2012-03-31	2013-03-31
Turnover
Cash turnover	22.72day	46.83day	30.22day	25.12day	-
Receivables turnover	75.99day	70.48day	82.28day	81.93day	-
Inventory turnover	34.65day	38.61day	41.52day	46.01day	-
Fixed assets turnover	46.96day	72.16day	116.78day	125.18day	-
Total asset turnover	614.10day	644.65day	672.14day	1,026.97day	1,121.12day
Payable turnover	19.99day	19.62day	24.97day	25.22day	-
Capital turnover	26.53day	26.60day	27.54day	27.78day	-
Equity turnover	505.99day	536.42day	548.27day	656.58day	706.08day
Working capita turnover	90.65day	89.47day	98.83day	102.72day	-
Indicator	2009-03-31	2010-03-31	2011-03-31	2012-03-31	2013-03-31
Balance sheet
Cash etc.	¥ 54 B	¥ 111 B	¥ 69 B	¥ 57 B	-
Accounts receivable-trade	¥ 181 B	¥ 168 B	¥ 189 B	-	-
Other Current Assets	¥ 655 B	¥ 626 B	¥ 569 B	¥ 580 B	-
Current Assets	¥ 709 B	¥ 737 B	¥ 639 B	-	-
Tangible Assets	¥ 112 B	¥ 172 B	¥ 269 B	¥ 286 B	-
Intangible Assets	¥ 4 B	¥ 7 B	¥ 13 B	¥ 18 B	-
Investment etc.	¥ 644 B	¥ 622 B	¥ 627 B	¥ 1.4 T	¥ 2.4 T
Total Assets	¥ 1.4 T	¥ 1.5 T	¥ 1.5 T	¥ 2.3 T	¥ 2.4 T
Current Liabilities	¥ 244 B	¥ 245 B	¥ 265 B	¥ 524 B	¥ 898 B
Fixed Liabilities	¥ 14 B	¥ 13 B	¥ 20 B	¥ 322 B	-
Liabilities with interest	-	-	-	¥ 569 B	-
Net Assets	¥ 1.2 T	¥ 1.2 T	¥ 1.2 T	¥ 1.5 T	¥ 1.5 T
Capital stock	¥ 63 B	¥ 63 B	¥ 63 B	¥ 63 B	-
Capital surplus etc.	¥ 1.1 T	¥ 1.2 T	¥ 1.2 T	¥ 1.4 T	¥ 1.5 T
Liabilities and net assets	¥ 1.4 T	¥ 1.5 T	¥ 1.5 T	-	-
Indicator	2009-03-31	2010-03-31	2011-03-31	2012-03-31	2013-03-31
Income statement
Sales	¥ 874 B	¥ 871 B	¥ 842 B	¥ 834 B	¥ 789 B
Cost of Sales	¥ 228 B	¥ 228 B	¥ 261 B	¥ 271 B	¥ 634 B
Gross profit	¥ 645 B	¥ 643 B	¥ 580 B	¥ 563 B	¥ 155 B
Other income	¥ 33 B	¥ 29 B	¥ 26 B	¥ 301 B	-
SG&A	¥ 402 B	¥ 396 B	¥ 398 B	¥ 384 B	-
Other expenses	¥ 127 B	¥ 70 B	¥ 73 B	¥ 108 B	-
Net income	¥ 149 B	¥ 206 B	¥ 135 B	¥ 372 B	¥ 155 B
Operating income	¥ 243 B	¥ 247 B	¥ 182 B	¥ 178 B	¥ 88 B
Ordinary Income	¥ 269 B	¥ 257 B	¥ 193 B	¥ 451 B	¥ 96 B
EBITDA	¥ 233 B	¥ 256 B	¥ 194 B	¥ 469 B	-
Income before income taxes	¥ 234 B	¥ 257 B	¥ 193 B	-	-
Depreciation	¥ 128 M	-	-	-	-
R&D expenses	-	-	-	-	-
Income taxes	¥ 84 B	¥ 50 B	¥ 58 B	-	-
Indicator	2009-03-31	2010-03-31	2011-03-31	2012-03-31	2013-03-31
Cash flow statement
Operating CF	-	-	-	-	-
Investment CF	-	-	-	-	-
Financial CF	-	-	-	-	-
Foreign Exchange Effects	-	-	-	-	-
Net Change in Cash	-	-	-	-	-
Free CF	-	-	-	-	-
Capital expenditures	-	-	-	-	-
Cash dividends paid	-	-	-	-	-
Repayment loans	-	-	-	-	-
Indicator	2009-03-31	2010-03-31	2011-03-31	2012-03-31	2013-03-31
Shareowners' equity
Issuance of new shares	-	-	-	-	-
Dividends from surplus	¥ -142 B	¥ -143 B	¥ -142 B	-	-
Net income	¥ 149 B	¥ 206 B	¥ 135 B	-	-
Purchase of treasury stock	¥ -280 B	¥ 77 M	¥ -35 M	-	-
Other Change in Stockholders Equity	-	¥ 1 M	-	-	-
Other Change in Net Assets	¥ -41 B	¥ 6 B	¥ -9 B	-	-
Net Change in Net Assets	¥ -314 B	¥ 69 B	¥ -16 B	-	-

Free Download

*Free Download Financial Indicator dataMember limited service.

[Data] Net Profit Margin, Sales Growth, Equity Margin etc., 100 or more kinds of financial indicators. (*Consolidated or Non-Consolidated. two or more terms)

Sponsored Link

Related Information: Takeda Pharmaceutical (Annual )

Statement Type

Annual : Takeda Pharmaceutical

First quarter : Takeda Pharmaceutical

Second quarter : Takeda Pharmaceutical

Third quarter : Takeda Pharmaceutical

Analysis Menu

Outline : Takeda Pharmaceutical

Statement : Takeda Pharmaceutical

Rating : Takeda Pharmaceutical

Indicator : Takeda Pharmaceutical

Download : Takeda Pharmaceutical

Industry Comparison Ranking

Chemicals - EDIUNET Industry Rankings

Chemicals - EDIUNET Credit Rating

Chemicals - EDIUNET Industry Avg

Comparison with a neighboring company

Osaka - EDIUNET Prefectures

Osaka大阪市 - EDIUNET Prefectures

Related company's newest statement

Date	Company	Credit Rating	Date
1/23	Milbon	AA→AAA	2013-12-20
1/17	Kawaguchi Chemical Indu..	BBB→BB	2013-11-30
1/17	SANKEI CHEMICAL	A	2013-11-30
1/15	HOKKO CHEMICAL INDUSTRY	BB→B	2013-11-30
1/15	Daito Pharmaceutical Co .	AA	2013-11-30 (Q2)
1/15	KAWAKAMI PAINT MFG.	B→BB	2013-11-30
1/15	旭化学工業	AA	2013-11-30 (Q1)
1/10	OSAKA ORGANIC CHEMICAL ..	BB→BBB	2013-11-30
1/10	HISAMITSU PHARMACEUTICAL	A	2013-11-30 (Q3)
1/10	AMS Life Science	BBB→BB	2013-11-30 (Q1)

EDIUNET Investment News (Chemicals)

1/23 Chemicals (Milbon:AA→AAA)

1/17 Chemicals (Kawaguchi Chemica..

1/15 Chemicals (HOKKO CHEMICAL IN..

1/10 Chemicals (OSAKA ORGANIC CHE..

1/9 Chemicals (SANKO GOSEI:A)

12/27 Chemicals (Niitaka:A)

12/18 Chemicals (KUMIAI CHEMICAL I..

12/12 Chemicals (IHARA CHEMICAL IN..

12/11 Chemicals (Konoshima Chemica..

12/10 Chemicals (NATOCO:AA)

Company Information

Ticker	Market	Industry	Month	report	Rating
Takeda Pharmaceutical	4502	TSE 1st	Chemicals	3	Annual	A

Related Company

Nihon Parkrizing (Sales ¥ 89 B)

Sekisui Chemical (Sales ¥ 1.0 T)

持田製薬 (Sales ¥ 89 B)

NIPPON PAINT (Sales ¥ 233 B)

Dainippon Sumitomo Pharma (Sales ¥ 347 B)

Hitachi Chemical (Sales ¥ 464 B)

ADEKA (Sales ¥ 184 B)

The Nippon Synthetic Chemical Industry (Sales ¥ 91 B)

キッセイ薬品工業 (Sales ¥ 62 B)

Toray Industries (Sales ¥ 1.5 T)

Mitsubishi Tanabe Pharma (Sales ¥ 419 B)

エスケー化研 (Sales ¥ 82 B)

Takeda Pharmaceutical (Sales ¥ 1.5 T)

関連する株式投資情報

EDIUNET Caution

*Financial data might be different from the actual one. Please confirm the original, and read Caution.

*This site has obtained the information from the FSA's EDINET, Tokyo Stock Exchange's TDnet and Pay statistical data services, Fukuoka stock Exchange's Stock market capitalization, Center for Spatial Information Science's CSV Geocoding Service. The copyright of the information belongs to each corporation etc. .